Clinical Update

Six Tips From Prescribing Psychotropics

Topics: Antipsychotic | Bupropion | Dosing | Lithium | olanzapine | Psychotropic medication | Side Effects

Every day we are faced with prescribing dilemmas that don’t have ready answers. Instant or extended release? Brand or generic? With food or without? How should we adjust dosing to account for drug interactions, age, gender, ethnicity, or genetic testing results? Our new textbook Prescribing Psychotropics: From Drug Interactions to Pharmacogenetics is

Read More
Expert Q&A

Combination Treatment for Schizophrenia

Topics: Adjunct treatment | Antidepressant | Antipsychotic | Benzodiazepine | CATIE | Combination treatment | Free Articles | Mood stabilizer | Outcomes | Psychopharmacology | Schizoaffective disorder | Schizophrenia | Substance Use Disorder

CHPR: You recently published a study on the use of adjunctive medications in patients with schizophrenia (Stroup TS et al, JAMA Psychiatry 2019;76(5):508–515). Your findings were provocative as you found that adjunctive medications often help improve patients’ outcomes, yet many clinicians avoid polypharmacy because of concern that patients will exp

Read More
Research Update

Antipsychotics for Methamphetamine Psychosis

Topics: Antipsychotic | Meta-analysis | Methamphetamines | Psychosis

REVIEW OF: Srisurapanont M et al, Drug Alcohol Depend 2021;219:108467 STUDY TYPE: Systematic review and network meta-analysis Methamphetamine psychosis (MAP) is difficult to treat, and there are only so many antipsychotics in our repertoire. Randomized clinical trials (RCTs) to manage MAP are few and far between, and the literature thus far has in

Read More
News of Note

An Antipsychotic Patch

Topics: Antipsychotic | Asenapine | News of Note | Patch | Saphris | Secuado | Transdermal

Asenapine (Saphris) is now available as a transdermal patch, Secuado. The patch showed efficacy in a large 6-week, double-blind, placebo-controlled, fixed-dose study in 616 adult patients with schizophrenia. Transdermal medications are thought to reduce side effects by avoiding “first-pass” metabolism in the GI tract. This is unlikely to be an adva

Read More